Persistent Asset Partners Ltd Sells 71,539 Shares of TG Therapeutics, Inc. $TGTX
Persistent Asset Partners Ltd significantly reduced its stake in TG Therapeutics, Inc. ($TGTX) by selling 71,539 shares, decreasing their holdings by 83.6% to 14,041 shares valued at $507,000. Other institutional investors like Public Sector Pension Investment Board and Jump Financial LLC either increased their positions or initiated new ones. The article also covers the company's stock performance, insider trading activity, and recent analyst ratings, which currently average a "Moderate Buy" with a consensus price target of $50.00.
Assessing TG Therapeutics (TGTX) Valuation After Long Term BRIUMVI Multiple Sclerosis Data Release
TG Therapeutics (TGTX) is being re-evaluated after releasing five-year data for its BRIUMVI multiple sclerosis treatment, showing durable efficacy and safety. Despite a recent share price decline, the stock has a three-year return of 72.96% and is considered "Undervalued" by Simply Wall St with a fair value of $44.43. The company's valuation relies on accelerating revenue from BRIUMVI and strong market penetration, though rising competition and potential setbacks pose risks.
Is TG Therapeutics (TGTX) Pricing Reflect Its DCF Upside And Recent BRIUMVI Milestones
TG Therapeutics (TGTX) appears significantly undervalued based on a Discounted Cash Flow (DCF) analysis, suggesting a 78.7% undervaluation with an estimated intrinsic value of $136.34 per share compared to its current price around $29. The stock's P/E ratio of 9.49x is also lower than both the biotech industry average and its calculated "Fair Ratio," further indicating undervaluation. The article presents bullish and bearish narratives for TG Therapeutics, highlighting the importance of its drug BRIUMVI's future performance and market perception.
5-year MS study: BRIUMVI patients average one relapse every 50 years
TG Therapeutics (NASDAQ: TGTX) published five-year data in JAMA Neurology for its multiple sclerosis drug, BRIUMVI, showing sustained efficacy and a consistent safety profile. The study revealed a very low annualized relapse rate of 0.020 in the fifth year, equivalent to one relapse every 50 patient-years, and more than 70% of participants remained on treatment. These findings support BRIUMVI's long-term benefits and its role as a valuable treatment option for relapsing multiple sclerosis.
TG Therapeutics, Inc. $TGTX Shares Bought by Public Sector Pension Investment Board
Public Sector Pension Investment Board significantly increased its stake in TG Therapeutics (NASDAQ:TGTX) by 14.5%, now holding 529,271 shares valued at approximately $19.12 million. Several other institutional investors also boosted their positions, contributing to an overall institutional ownership of 58.58%. While analysts maintain a "Moderate Buy" consensus rating with a $50 price target, a director recently sold 5,000 shares, reducing their personal stake.
TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of "Moderate Buy" from Brokerages
TG Therapeutics, Inc. (NASDAQ:TGTX) has received an average rating of "Moderate Buy" from six brokerages, with an average one-year target price of $50.00. Insider transactions show Director Yann Echelard selling 5,000 shares in November, while institutional investors hold 58.58% of the company's stock. The company's shares opened at $28.50, with a market capitalization of $4.52 billion and a P/E ratio of 10.25.
Goldman Sachs raises TG Therapeutics, Inc. (TGTX) target to $39 on 2026 guidance
Goldman Sachs has increased its price target for TG Therapeutics (TGTX) to $39, citing the company's strong guidance for 2026. This upward revision reflects Goldman Sachs' confidence in TG Therapeutics' future performance and financial outlook.
TG Therapeutics lights up Super Bowl with Christina Applegate MS campaign — retail sees 'huge win'
TG Therapeutics launched a national Super Bowl ad campaign featuring actress Christina Applegate to raise awareness for Multiple Sclerosis (MS) and their drug Briumvi. The campaign, which included commercials during the Super Bowl and integrations with major sports and news outlets, is seen as a significant victory for retail investors. The effort aims to reach a large audience and educate them about MS and treatment options.
Assessing TG Therapeutics (TGTX) Valuation After New BRIUMVI Data And Christina Applegate MS Campaign
TG Therapeutics (TGTX) is gaining attention after new BRIUMVI data for relapsing multiple sclerosis and a national MS awareness campaign featuring Christina Applegate. Despite a recent 1-month share price increase of 3.9%, the stock has seen an 8.3% decline over the past year. Simply Wall St assesses TGTX as undervalued, with a fair value of $44.43 against its current price of $29.58, largely due to the potential launch of subcutaneous BRIUMVI expanding its market reach.
TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis
TG Therapeutics has partnered with actress Christina Applegate to launch the "Next In MS" campaign, a national disease-awareness initiative focused on raising awareness of multiple sclerosis and fostering honest conversations among those living with the condition. The campaign, which debuted during Super Bowl LX, features a new digital platform, www.NextInMS.com, where Applegate shares her personal experiences and perspectives on navigating life with MS. The goal is to provide a space for open dialogue among patients, caregivers, and healthcare professionals and to empower individuals living with MS.
TG Therapeutics Lights Up Super Bowl With Christina Applegate MS Campaign — Retail Sees 'Huge Win'
TG Therapeutics (TGTX) has launched the NextInMS platform and a Super Bowl campaign featuring Christina Applegate to raise awareness for multiple sclerosis (MS). This initiative aims to drive further growth for its key drug, Briumvi, which is projected to generate significant global revenue in 2026. The campaign has sparked bullish sentiment among retail investors, with Wall Street analysts also seeing considerable upside for TGTX stock.
Christina Applegate fronts new MS honesty campaign with TG Therapeutics
TG Therapeutics has partnered with actress Christina Applegate to launch "Next In MS," a national disease-awareness initiative to foster honest conversations about multiple sclerosis. The campaign, which debuted during Super Bowl LX, includes a new platform, www.NextInMS.com, offering personal perspectives from Applegate and educational content from experts to support individuals, caregivers, and healthcare professionals navigating life with MS. The collaboration aims to elevate patient voices and provide resources for long-term decision-making and healthcare navigation.
TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis
TG Therapeutics has partnered with actress Christina Applegate to launch a national disease-awareness initiative focused on multiple sclerosis (MS). Applegate, who has lived with MS for five years, will lead the campaign, which includes the new platform www.NextInMS.com. This platform aims to foster honest conversations among individuals living with MS, providing shared experiences and educational content.
TG Therapeutics Partners with Christina Applegate to Raise MS Awareness
TG Therapeutics has partnered with actress Christina Applegate to launch a national awareness campaign for multiple sclerosis (MS) named www.NextInMS.com. This initiative aims to foster open dialogue, share personal experiences, and provide educational content from MS experts to help patients, caregivers, and healthcare professionals better understand and cope with the disease. CEO Michael S. Weiss emphasized the company's commitment to patient needs, ensuring that their voices guide the development of new therapies and support resources.
How Investors Are Reacting To TG Therapeutics (TGTX) New BRIUMVI Real-World Data And Pediatric Trials
TG Therapeutics presented new real-world data and progress on pediatric trials for its multiple sclerosis drug, BRIUMVI, at the ACTRIMS annual forum. This data supports the drug's clinical footprint and its ongoing investment narrative, reinforcing its presence in clinical use and its expansion into new age groups. While the new information incrementally supports existing expectations, key factors like market competition and real-world safety outcomes remain significant for the company's future
TG Therapeutics (TGTX) Sees Price Target Drop from JPMorgan
JPMorgan analyst Brian Cheng reduced the price target for TG Therapeutics (TGTX) to $46 from $49, while maintaining an Overweight rating, following an update to their model and the company's presentation of Briumvi trial results. This comes after earlier Buy ratings from H.C. Wainwright and TD Cowen, citing strong commercial momentum and anticipated clinical catalysts for their multiple sclerosis treatment. The article also mentions a recommendation to consider AI stocks with greater upside potential.
TG Therapeutics Announces Presentation of Data for BRIUMVI®
TG Therapeutics announced the presentation of new data for BRIUMVI (ublituximab-xiiy) in multiple sclerosis at the ACTRIMS annual forum. The presentations include real-world infusion experience, a Phase 2 dose confirmation study design for pediatric RMS, and a Phase 3 study design comparing ublituximab to fingolimod in children and adolescents with RMS. This data aims to advance the clinical understanding and support for the MS community regarding BRIUMVI.
TG Therapeutics Presents BRIUMVI Data at ACTRIMS Annual Meeting
TG Therapeutics presented clinical data for its drug BRIUMVI at the ACTRIMS annual meeting, highlighting updates from the ENABLE study and the design of the ULTIMATE I and II trials for relapsing multiple sclerosis. BRIUMVI, a novel monoclonal antibody targeting CD20-positive B cells, aims to provide an effective new treatment option. Wall Street analysts maintain a "Moderate Buy" rating for TGTX, with an average 1-year price target of $43.50, despite recent stock underperformance compared to major indices.
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
TG Therapeutics announced the presentation of new data for BRIUMVI (ublituximab) in multiple sclerosis at the ACTRIMS annual forum. The presentations include updates from the ENABLE real-world study and study designs for Phase 2 and Phase 3 trials (ULTIMATE KIDS I and II) evaluating ublituximab in pediatric patients with relapsing multiple sclerosis. This highlights TG Therapeutics' commitment to advancing the understanding and application of BRIUMVI for the MS community.
TG Therapeutics Presents New Data on BRIUMVI® at ACTRIMS 2026 Annual Forum
TG Therapeutics announced the presentation of new data for its drug BRIUMVI® (ublituximab-xiiy) at the ACTRIMS annual forum. The data included updates from the ENABLE real-world study and studies for children and adolescents with relapsing multiple sclerosis (RMS), reinforcing the company's commitment to advancing understanding and expanding treatment options for BRIUMVI. The article also highlights critical safety information, potential risks, and financial data related to TGTX, including insider trading, revenue, hedge fund activity, and analyst ratings.
TG Therapeutics Announces Presentation of Data for BRIUMVI®
TG Therapeutics announced the presentation of new data for BRIUMVI (ublituximab-xiiy) at the ACTRIMS annual forum. The presentations include real-world infusion experiences, study designs for pediatric trials (ULTIMATE KIDS I and II), and biomarker test results. BRIUMVI is an FDA-approved treatment for adults with relapsing forms of multiple sclerosis.
Real-world and pediatric MS data put BRIUMVI under spotlight at ACTRIMS
TG Therapeutics (NASDAQ: TGTX) announced the presentation of new data for its multiple sclerosis drug, BRIUMVI (ublituximab), at the ACTRIMS annual forum on February 6, 2026. The presentations include real-world infusion data from the ENABLE study and design details for the pediatric ULTIMATE KIDS I and II trials. These insights aim to advance the clinical understanding of BRIUMVI and support the MS community, with further details available on the company's website and the ACTRIMS ePoster gallery.
Why (TGTX) Price Action Is Critical for Tactical Trading
This article analyzes Tg Therapeutics Inc. (NASDAQ: TGTX) stock's critical price action for tactical trading, identifying a near-term weak sentiment that might lead to long-term weakness. It highlights a 50.1:1 risk-reward setup, targeting a 15.1% gain versus 0.3% risk, and outlines three AI-generated trading strategies (Position Trading, Momentum Breakout, and Risk Hedging) tailored for different risk profiles and holding periods, alongside multi-timeframe signal analysis.
TG Therapeutics (NASDAQ:TGTX) Takes On Some Risk With Its Use Of Debt
TG Therapeutics (TGTX) utilizes debt in its business, holding US$246.2 million in debt against US$131.6 million in cash, resulting in net debt of US$114.6 million. While the company's liquid assets appear well-balanced against total liabilities and its net debt to EBITDA and interest cover ratios are reasonable, its significant free cash flow burn in the past year indicates a higher risk associated with its debt. Despite an improved EBIT, the inability to convert earnings to cash adds a layer of concern for investors.
JPMorgan Chase & Co. Issues Pessimistic Forecast for TG Therapeutics (NASDAQ:TGTX) Stock Price
JPMorgan Chase & Co. lowered its price target for TG Therapeutics (NASDAQ:TGTX) from $49.00 to $46.00 but maintained an "overweight" rating, suggesting a significant upside of 57.83%. Despite the target reduction, the biopharmaceutical company holds a consensus "Moderate Buy" rating with an average target of $50.00 from other analysts. TG Therapeutics recently reported strong quarterly earnings, with EPS of $2.43 well above estimates and revenue growth of 92.7% year-over-year.
Universal Beteiligungs und Servicegesellschaft mbH Has $2.29 Million Stake in TG Therapeutics, Inc. $TGTX
Universal Beteiligungs und Servicegesellschaft mbH reduced its stake in TG Therapeutics by 67.1%, selling 129,025 shares and retaining 63,298 shares valued at approximately $2.29 million. Other institutional investors like Jump Financial LLC and Marex Group plc increased their holdings or initiated new positions in the biopharmaceutical company. TG Therapeutics reported strong Q3 earnings, beating analyst expectations with $2.43 EPS and 92.7% year-over-year revenue growth.
TG Therapeutics Readies New BRIUMVI Data As Market Weighs Valuation
TG Therapeutics (NasdaqCM:TGTX) is preparing to release new clinical data for its drug BRIUMVI at the upcoming ACTRIMS annual forum. This data will include real-world infusion experiences, pediatric trial designs, and biomarker findings for relapsing multiple sclerosis, aiming to further define BRIUMVI's clinical profile. The market is currently weighing the valuation of TG Therapeutics, with the stock showing significant volatility, trading below analyst targets and flagged as undervalued by Simply Wall St.
TG Therapeutics Readies New BRIUMVI Data As Market Weighs Valuation
TG Therapeutics (NasdaqCM:TGTX) is preparing to release new clinical data for its drug BRIUMVI at the upcoming ACTRIMS annual forum, which includes Phase 4 real-world infusion experience, pediatric trial designs, and biomarker findings in relapsing multiple sclerosis. This data aims to further define BRIUMVI's clinical profile and is drawing investor attention as the market assesses the drug's revenue potential and the company's valuation. While the stock is currently flagged as undervalued by Simply Wall St, investors are advised to watch the safety and infusion experience details and consider the risk of high non-cash earnings.
TG Therapeutics Announces Schedule of Data Presentations
TG Therapeutics announced its schedule of data presentations for BRIUMVI (ublituximab) in Multiple Sclerosis at the upcoming ACTRIMS annual forum in San Diego from February 5-7, 2026. The presentations will include real-world infusion experience, and study designs for Phase 2 and Phase 3 trials in children and adolescents with Relapsing Multiple Sclerosis (RMS). The company also provided important safety information and details about BRIUMVI's mechanism of action and patient support program.
TG Therapeutics to present BRIUMVI data at ACTRIMS forum
TG Therapeutics (NASDAQ:TGTX) is set to present new data on its multiple sclerosis treatment, BRIUMVI (ublituximab), at the ACTRIMS annual forum in February 2026. The presentations will include real-world observational data and details on upcoming pediatric clinical trials for the drug. This news follows a strong financial performance for the company in 2025, with BRIUMVI contributing significantly to its global revenue, and positive analyst assessments.
TG Therapeutics Readies New BRIUMVI Data As Market Weighs Valuation
TG Therapeutics (NasdaqCM:TGTX) plans to present new clinical data for BRIUMVI at the upcoming ACTRIMS annual forum, covering real-world infusion experience, pediatric trial designs, and biomarker findings in relapsing multiple sclerosis. This data package aims to further define BRIUMVI's clinical profile and is drawing attention to the company's valuation, as its shares are currently flagged as undervalued. Investors will be watching how this new data compares to existing treatments and addresses practical usage in patient care.
TG Therapeutics to present BRIUMVI data at ACTRIMS forum By Investing.com
TG Therapeutics (NASDAQ:TGTX) announced it will present data on its multiple sclerosis drug, BRIUMVI, at the ACTRIMS annual forum. The presentations will include a Phase 4 observational study on real-world infusion experience, as well as designs for two pediatric clinical trials. This news follows a strong financial performance in 2025, with significant revenue from BRIUMVI and positive analyst outlooks.
TG Therapeutics to present BRIUMVI data at ACTRIMS forum By Investing.com
TG Therapeutics (NASDAQ:TGTX) has announced it will present new data on its multiple sclerosis drug, BRIUMVI, at the upcoming ACTRIMS forum from February 5-7, 2026. The presentations will include findings from a Phase 4 observational study, as well as designs for pediatric clinical trials. The company also reported strong preliminary financial results for 2025, with total global revenue of approximately $616 million, largely driven by BRIUMVI sales.
TGTX Stock Price, Forecast & Analysis | TG THERAPEUTICS INC (NASDAQ:TGTX)
TG Therapeutics Inc. (NASDAQ:TGTX) stock is currently priced at $30.47, reflecting a slight increase in the last trading session but a decrease over the past month and year. Analysts forecast a significant price increase of 49.21% over the next year, with expected EPS growth of 2068.02% and revenue growth of 90.61%. The company focuses on developing and commercializing treatments for B-cell malignancies and autoimmune diseases.
TG Therapeutics to present BRIUMVI data at ACTRIMS forum By Investing.com
TG Therapeutics (NASDAQ:TGTX) announced it will present new data for its multiple sclerosis drug, BRIUMVI (ublituximab-xiiy), at the ACTRIMS forum in February 2026. The presentations will include real-world observational study results and designs for pediatric clinical trials. The company also reported strong preliminary financial results for 2025, with BRIUMVI sales significantly exceeding expectations and positive guidance for 2026.
BRIUMVI multiple sclerosis data to headline San Diego ACTRIMS forum
TG Therapeutics (NASDAQ: TGTX) announced its schedule of BRIUMVI (ublituximab-xiiy) data presentations for multiple sclerosis at the ACTRIMS Annual Forum in San Diego from February 5–7, 2026. The presentations will cover real-world Phase 4 infusion experience (ENABLE), pediatric dose-confirmation (ULTIMATE KIDS I), comparative design versus fingolimod (ULTIMATE KIDS II), and biomarker results from ENHANCE. This continues TG Therapeutics' strategy to broaden BRIUMVI's profile and support its strong financial performance.
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
TG Therapeutics (NASDAQ: TGTX) announced its schedule of data presentations for BRIUMVI (ublituximab) at the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, taking place from February 5-7, 2026, in San Diego, California. The presentations will include real-world infusion experience, study designs for pediatric relapsing multiple sclerosis trials (ULTIMATE KIDS I and II), and biomarker test results. BRIUMVI is an FDA-approved treatment for adults with relapsing forms of multiple sclerosis, featuring a novel glycoengineered anti-CD20 monoclonal antibody designed for efficient B-cell depletion.
A Look At TG Therapeutics (TGTX) Valuation After Updated BRIUMVI Revenue Outlook
TG Therapeutics (TGTX) has provided updated revenue figures for Q4 and FY 2025, along with 2026 guidance, offering insight into BRIUMVI's performance and future growth. The stock is currently trading below its estimated intrinsic value and analyst price targets, suggesting it may be undervalued. The upcoming launch of subcutaneous BRIUMVI is a key catalyst expected to significantly expand its addressable market.
A Look At TG Therapeutics (TGTX) Valuation After Updated BRIUMVI Revenue Outlook
TG Therapeutics (TGTX) has released preliminary Q4 and full-year 2025 revenue figures and 2026 guidance for its drug BRIUMVI, providing new insights into the company's financial outlook. The stock is currently trading below its estimated intrinsic value and analyst price targets, suggesting it could be undervalued. A key future catalyst is the planned launch of subcutaneous BRIUMVI, which is expected to significantly expand its addressable market in the anti-CD20 MS segment.
Understanding Momentum Shifts in (TGTX)
This article provides an analysis of Tg Therapeutics Inc. (TGTX), highlighting a strong near and mid-term sentiment but a weak long-term outlook. It identifies resistance testing and outlines institutional trading strategies, including long, breakout, and risk hedging, based on AI-generated signals and multi-timeframe analysis. The analysis also emphasizes risk-reward scenarios and provides support and resistance levels for various time horizons.
Is TG Therapeutics (TGTX) Pricing Reflecting Its Strong DCF And P/E Valuation Signals?
TG Therapeutics (TGTX) appears undervalued based on a Discounted Cash Flow (DCF) analysis, with an estimated intrinsic value significantly higher than its current share price. The company also screens as undervalued on a Price-to-Earnings (P/E) basis, trading below both its industry average and its proprietary "Fair Ratio." These valuation signals suggest potential opportunity, though the article emphasizes using investor "Narratives" for a more personalized analysis.
Is TG Therapeutics (TGTX) Pricing Reflecting Its Strong DCF And P/E Valuation Signals?
TG Therapeutics (TGTX) is currently trading at US$31.63, with analysis suggesting it is significantly undervalued. A Discounted Cash Flow (DCF) analysis estimates its intrinsic value at $131.33, implying a 75.9% discount. Furthermore, its current P/E ratio of 10.33x is below both the industry average and Simply Wall St’s Fair Ratio of 18.95x, reinforcing the view that the stock is undervalued based on essential financial metrics.
Why TG Therapeutics (TGTX) Is Up 6.9% After Issuing 2026 BRIUMVI-Centric Revenue Guidance And What's Next
TG Therapeutics (TGTX) saw its stock rise by 6.9% after announcing strong preliminary 2025 results and issuing 2026 revenue guidance, heavily centered on its drug BRIUMVI. The company projects global revenue of US$875–900 million for 2026, with BRIUMVI U.S. net product revenue accounting for a significant portion. While this reinforces BRIUMVI's importance and may boost near-term sentiment, it also highlights risks associated with product concentration and competition.
Why TG Therapeutics (TGTX) Is Up 6.9% After Issuing 2026 BRIUMVI-Centric Revenue Guidance And What's Next
TG Therapeutics (TGTX) saw a 6.9% stock increase after providing 2026 revenue guidance heavily reliant on its drug BRIUMVI. The company projects global revenue of US$875–900 million, with BRIUMVI U.S. net product sales expected to range between US$825–850 million. This update reinforces the company's concentration around a single commercial asset, highlighting both the growth potential and the significant product concentration risk for investors.
TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of "Moderate Buy" from Brokerages
TG Therapeutics, Inc. (NASDAQ:TGTX) has received a consensus "Moderate Buy" rating from six brokerages, with an average 1-year price target of $50.75. This is supported by recent upgrades and strong Q4 earnings that significantly beat analyst expectations. The company also shows notable insider and institutional ownership.
TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results
TG Therapeutics (TGTX) shares increased by nearly 7% following the release of strong preliminary Q4 and full-year 2025 results, which surpassed expectations. The company also provided bullish guidance for 2026, projecting total revenues between $875 million and $900 million, and outlined key milestones for its Briumvi label expansion studies and other pipeline candidates. Despite a recent decline in share price, the preliminary sales figures for Briumvi exceeded previous guidance and analyst estimates.
Goldman Sachs Raises TG Therapeutics Price Target to $39, Briumvi Now Available in 16 Countries
Goldman Sachs has increased its price target for TG Therapeutics to $39 from $37, maintaining a 'neutral' rating and suggesting significant upside potential. This comes as TG Therapeutics' CEO, Michael Weiss, announced Briumvi's availability in 16 countries with over 20,000 patients, setting a strong foundation for future revenue. The company anticipates Briumvi's U.S. revenue to reach $825-$850 million, contributing to a total forecast of $875-$900 million by 2026, amid improving retail investor sentiment for the stock.
A Look At TG Therapeutics (TGTX) Valuation After New BRIUMVI Revenue Guidance At J.P. Morgan Conference
TG Therapeutics (TGTX) recently provided fresh revenue guidance for its drug BRIUMVI at the J.P. Morgan Healthcare Conference, influencing its stock valuation. Despite a recent share price decline, the longer-term performance remains strong. Analysts generally view the stock as undervalued, forecasting significant growth due to BRIUMVI's potential, though product concentration risk remains a key concern.
TG Therapeutics Target of Unusually Large Options Trading (NASDAQ:TGTX)
TG Therapeutics (NASDAQ:TGTX) experienced unusually large options trading activity, with traders purchasing 7,870 call options, marking a 119% increase over the average. This surge in bullish interest coincided with a 4.7% rise in the company's stock to $29.18 on heavy trading volume. The biopharmaceutical company recently reported strong quarterly earnings, beating analyst expectations with an EPS of $2.43 against a forecasted $0.24, and analysts maintain a "Moderate Buy" rating with an average price target of $50.25.
TG Therapeutics Soars on Strong Revenue Guidance and BRIUMVI Momentum
TG Therapeutics (TGTX) saw its stock surge after providing strong revenue guidance for FY25 and FY26, largely driven by its key product, BRIUMVI. The company anticipates significant growth in BRIUMVI revenue, fueled by upcoming lifecycle initiatives like consolidated IV dosing and a self-administered subcutaneous formulation. TGTX also plans to expand BRIUMVI's use beyond multiple sclerosis and advance its pipeline with azer-cel, a new drug candidate.
